BONESUPPORT receives "breakthrough device designation" for CERAMENT G for the indication trauma
Lund, Sweden, 10:00 CET, 17 06 21 BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company's antibiotic eluting product CERAMENT G has been categorized as a breakthrough device for the indication trauma by the US Food and Drug Administration (FDA). The categorization “breakthrough device” can be assigned to products that are considered to provide a more effective treatment of severe disease states, where there is no comparable equivalent on the market. The categorization is intended to expedite the regulatory review of